Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004497 | 0.89 | BMP1 (0.89) | BMP1 | |
| SCHEMBL7002992 | 0.87 | BMP1 (1.00) | BMP1 | |
| SCHEMBL6999380 | 0.87 | BMP1 (1.00) | BMP1 | |
| SCHEMBL19180803 | 0.86 | BMP1 (0.76) | BMP1 | |
| SCHEMBL7008058 | 0.86 | BMP1 (1.00) | BMP1 | |
| SCHEMBL7001896 | 0.84 | BMP1 (1.00) | BMP1 | |
| SCHEMBL6997496 | 0.84 | BMP1 (0.89) | BMP1 | |
| SCHEMBL966229 | 0.83 | BMP1 (1.00) | BMP1 | |
| SCHEMBL1115835 | 0.82 | BMP1 (0.77) | BMP1 | |
| SCHEMBL30274504 | 0.82 | BMP1 (0.70) | BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322155-B1 | Use of HIF alpha stabilizers for enhancing erythropoiesis | FIBROGEN INC (US) | 2014-08-13 | — | — | EP | claimed |
| EP-2322155-A1 | Use of HIF alpha stabilizers for enhancing erythropoiesis | Fibrogen, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| EP-2322153-A1 | Use of HIF Alpha stabilizers for enhancing erythropoiesis | Fibrogen, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | claimed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20060251638-A1 | Cytoprotection through the use of hif hydroxylase inhibitors | FIBROGEN, INC. | 2006-11-09 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024165507-A1 | USE OF HIF-1Α STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-15 | — | — | WO | disclosed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11969417-B2 | Topical formulation for use in alopecia | TOMORROWLABS GMBH (AT) | 2024-04-30 | — | — | US | disclosed |
| EP-3917525-B1 | NEW TOPICAL FORMULATION FOR USE IN ALOPECIA | TOMORROWLABS GMBH (AT) | 2024-02-28 | — | — | EP | disclosed |
| WO-2005007192-A2 | CYTOPROTECTION THROUGH THE USE OF HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1487472-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004108121-A1 | USE OF HIF ALPHA STABILIZERS FOR ENHANCING ERYTHROPOIESIS | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | BMP1 2470/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | BMP1 4106/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | BMP1 368/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | BMP1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.